Sympathetic Activity in Individuals With the Metabolic Syndrome: Benefits of Lifestyle Interventions

  • STATUS
    Recruiting
  • participants needed
    66
  • sponsor
    Bayside Health
Updated on 7 November 2020
diabetes
insulin
body mass index
hypertension
fasting
type 2 diabetes mellitus
heart disease
hyperglycemia
plasma glucose
central obesity
plasma triglyceride level

Summary

An abdominal distribution of fat is associated with the greatest heart disease risk, because commonly, several risk factors of metabolic origin (high blood pressure, unfavourable cholesterol profile, elevated blood sugar, impaired insulin action) cluster in these individuals. When this occurs the condition is called the 'metabolic syndrome' (MetS). The cause of the MetS is yet to be fully elucidated. Increased activity of the nervous system resulting in enhanced release of the stress hormone 'norepinephrine', may be one mechanism by which adverse cardiovascular and metabolic sequelae of the MetS might be mediated. Dietary weight loss, and exercise are first-line treatments for the MetS and provide an opportunity to prevent or delay the development of type 2 diabetes and heart disease in this high risk group. However, there is a paucity of data regarding the effects of these lifestyle factors on the nervous system. Furthermore, it is also unknown whether active weight loss ('negative energy balance') or a stable lower weight (weight loss maintenance) is more important in modifying MetS components and nervous system activity. The aims of the proposed project are: 1. To determine whether dietary weight loss in combination with aerobic exercise is more beneficial than dietary weight loss alone in reducing nervous system activity and improving metabolic and cardiovascular parameters in middle-aged men and women with abdominal obesity and the MetS. 2. To determine whether weight loss maintenance four months after active weight loss is associated with a preservation of clinical benefits. 3. To study biological determinants of successful weight loss and weight loss maintenance.

Description

Background: Autonomic dysfunction, namely increased sympathetic drive and reduced vagal tone, may participate in the pathogenesis and complications of the MetS. Weight loss and aerobic exercise are first-line therapeutic strategies that are known to be beneficial in lowering blood pressure, enhancing insulin action and preventing the development of type 2 diabetes. However, there is a paucity of data regarding their effects on sympathetic nervous system (SNS) activity. In a recently completed Pilot study in 22 MS subjects we demonstrated that moderate dietary weight loss (7% of initial body weight) is associated with marked reductions in whole-body norepinephrine spillover rate (by 43%, P= 0.005) and muscle sympathetic nervous activity (MSNA, by 15%, P=0.01). In the proposed project we wish to extend these observations by evaluating the clinical benefits of aerobic exercise and weight loss maintenance. Aims: 1. To determine whether dietary weight loss in combination with aerobic exercise (WL + EX) is more beneficial than dietary weight loss alone (WL) in reducing SNS activity and improving cardiovascular and metabolic parameters in middle aged men and women with abdominal obesity and a diagnosis of the MetS. 2. To investigate the determinants of achieved weight loss, with a focus on the roles of SNS activity, b2-adrenoceptor polymorphisms, resting metabolic rate, plasma and interstitial adipocytokines. 3. To determine whether clinical benefits during active weight loss (negative energy balance) are sustained after a 4-month weight loss maintenance program and to investigate the determinants of successful weight loss maintenance (as above). 4. To examine the inter-relationships between SNS activity, insulin sensitivity, metabolic, anthropometric and haemodynamic parameters. Subjects: Sedentary men and women (n= 66) aged 45 to 65 years with a body mass index of 26 to 39 kg/m2, who fulfil Adult Treatment Panel III criteria for the MetS. Study design: Randomized, controlled, parallel design comparison of: 1. WL; 2. WL + EX; or 3. Control (no treatment). Investigations will be performed at baseline, and at the end of 3-month lifestyle intervention, and a 4-month weight-maintenance program (WL and WL + EX groups). Diets: A modified version of the 'DASH' diet will be used at different caloric levels. Exercise: Bicycle riding, performed for 40 minutes on alternate days at a moderate intensity of 65% of maximum heart rate. Compliance will be assessed by VO2 max measurements. Investigations: SNS activity measurements (multiunit and single-unit microneurographic recordings of MSNA, whole-body norepinephrine spillover, and abdominal adipose tissue and skeletal muscle interstitial noradrenaline concentration determined by microdialysis) will be made before and during an oral glucose tolerance test, together with haemodynamic (calf blood flow measured by venous occlusion plethysmography) measurements. Changes in fat mass will be quantitated by DEXA scan. Metabolic measurements will include resting metabolic rate, insulin sensitivity, lipid profile, non-esterified fatty acids, plasma and interstitial adipokines/cytokines. Clinical significance: The proposed project will provide novel information about whole-body and regional sympathetic activity; the determinants of sympathetic activity and the relative clinical benefits of active weight loss, weight loss maintenance and aerobic exercise in middle-aged MetS subjects.

Details
Condition Metabolic syndrome
Treatment Dietary weight loss +/- aerobic exercise
Clinical Study IdentifierNCT00163943
SponsorBayside Health
Last Modified on7 November 2020

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note